1. Home
  2. DBVT vs XNET Comparison

DBVT vs XNET Comparison

Compare DBVT & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • XNET
  • Stock Information
  • Founded
  • DBVT 2002
  • XNET 2003
  • Country
  • DBVT France
  • XNET China
  • Employees
  • DBVT N/A
  • XNET N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • XNET Computer Software: Prepackaged Software
  • Sector
  • DBVT Health Care
  • XNET Technology
  • Exchange
  • DBVT Nasdaq
  • XNET Nasdaq
  • Market Cap
  • DBVT 464.0M
  • XNET 481.7M
  • IPO Year
  • DBVT N/A
  • XNET 2014
  • Fundamental
  • Price
  • DBVT $14.36
  • XNET $8.08
  • Analyst Decision
  • DBVT Buy
  • XNET
  • Analyst Count
  • DBVT 5
  • XNET 0
  • Target Price
  • DBVT $15.85
  • XNET N/A
  • AVG Volume (30 Days)
  • DBVT 172.8K
  • XNET 438.7K
  • Earning Date
  • DBVT 10-28-2025
  • XNET 11-13-2025
  • Dividend Yield
  • DBVT N/A
  • XNET N/A
  • EPS Growth
  • DBVT N/A
  • XNET 5056.12
  • EPS
  • DBVT N/A
  • XNET 11.50
  • Revenue
  • DBVT $5,502,000.00
  • XNET $355,826,000.00
  • Revenue This Year
  • DBVT $1,743.46
  • XNET N/A
  • Revenue Next Year
  • DBVT $1,044.34
  • XNET N/A
  • P/E Ratio
  • DBVT N/A
  • XNET $0.76
  • Revenue Growth
  • DBVT N/A
  • XNET 11.15
  • 52 Week Low
  • DBVT $2.21
  • XNET $1.82
  • 52 Week High
  • DBVT $18.00
  • XNET $11.03
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 51.23
  • XNET 41.71
  • Support Level
  • DBVT $13.70
  • XNET $8.25
  • Resistance Level
  • DBVT $15.97
  • XNET $9.40
  • Average True Range (ATR)
  • DBVT 1.06
  • XNET 0.45
  • MACD
  • DBVT -0.40
  • XNET -0.16
  • Stochastic Oscillator
  • DBVT 15.71
  • XNET 1.17

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

Share on Social Networks: